以嶺藥業(002603.SZ):化藥創新藥G201-Na膠囊藥物臨牀試驗申請獲得受理
格隆匯7月12日丨以嶺藥業(002603.SZ)公佈,近日,石家莊以嶺藥業股份有限公司收到國家藥品監督管理局核准簽發的《受理通知書》。為G201-Na膠囊。
G201-Na膠囊項目是公司自主研發、具有獨立知識產權的1類化學新藥,其藥品分類為婦科用藥。
該品為小分子促性腺激素釋放激素(GnRH)受體拮抗劑。藥物通過與垂體GnRH受體競爭性結合,抑制垂體性腺軸,減少內源性促黃體生成素(LH)和卵泡刺激素(FSH)的生成和釋放,降低雌激素水平,從而治療雌激素依賴的相關疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.